Different Angiogenic Potential in Low and High Grade Sporadic Clear Cell Renal Cell Carcinoma Is Not Related to Alterations in the von Hippel–Lindau Gene
Different Angiogenic Potential in Low and High Grade Sporadic Clear Cell Renal Cell Carcinoma Is Not Related to Alterations in the von Hippel–Lindau Gene
Background: von Hippel–Lindau (VHL) inactivation is common in sporadic clear cell renal cell carcinomas (ccRCC). pVHL is part of the ubiquitin ligase complex that targets the alpha subunits of hypoxia-inducible transcription factor (HIF) for degradation under well-oxygenated conditions. In the absence of wild-type pVHL, as observed in VHL patients and most sporadic ccRCCs, constitutive upregulation of HIF results in transcriptional activation of angiogenesis-related genes, such as VEGF. Differences in angiogenic activity within the group of ccRCCs were reported and strong genotype-phenotype correlations were found in patients with VHL disease, raising a question about the importance of VHL inactivation status in angiogenic behaviour and tumour progression.Methods: To address this question, we investigated the influence of VHL mutation (direct sequencing)/hypermethylation (methylation-specific PCR) on angiogenesis/tumour parameters (immunohistochemistry) in 150 patients with sporadic ccRCC.Results: We found no significant association between VHL mutation or methylation and angiogenesis/tumour parameters.Conclusions: These data indicate that tumour progression and angiogenesis are not directly influenced by VHL alterations and that additional genetic/epigenetic events should be considered to explain the diverse angiogenic and proliferative behaviour during tumour progression.
- KU Leuven Belgium
- Maastricht University Netherlands
- Katholieke Universiteit Leuven Belgium
- University of Antwerp Belgium
- Antwerp University Hospital Belgium
Male, QH573-671, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, DNA Methylation, Immunohistochemistry, Kidney Neoplasms, Treatment Outcome, Von Hippel-Lindau Tumor Suppressor Protein, Mutation, Disease Progression, Humans, CpG Islands, Female, Human medicine, Other, Cytology, Hypoxia, Promoter Regions, Genetic, Carcinoma, Renal Cell, RC254-282, Aged
Male, QH573-671, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, DNA Methylation, Immunohistochemistry, Kidney Neoplasms, Treatment Outcome, Von Hippel-Lindau Tumor Suppressor Protein, Mutation, Disease Progression, Humans, CpG Islands, Female, Human medicine, Other, Cytology, Hypoxia, Promoter Regions, Genetic, Carcinoma, Renal Cell, RC254-282, Aged
10 Research products, page 1 of 1
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
- 2017IsRelatedTo
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).14 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
